SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as traders position ahead of the company's upcoming Q2 earnings report, with retail sentiment shifting to extremely bullish on expectations of a revenue and EPS beat given management's historically conservative guidanceconsensus calls for roughly $145.5 million in quarterly revenue, up more than 12% year over year. The QNX physical-AI narrative is amplifying the buzz: traders highlight NVIDIA's adoption of QNX 8.0 for automotive and physical AI operating systems, a Sift-QNX partnership to stream telemetry from physical AI systems, and speculation that an Alloy Kore win could soon become visible in the roughly $950 million QNX royalty backlog, which management previously said contained no Alloy Kore business. The community remains split, howeveran active short camp repeatedly urges 'short every pop' into the report, some skeptics argue past beats came only from lowered guidance, and longs counter that QNX's embedded-software footprint is deeply undervalued as they watch for a breakout from single-digit prices.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Speculation that Novo Nordisk could pursue a large acquisition or partnership of Viking Therapeutics is dominating the ticker, sparked by Novo's statement that its balance sheet could support deals well beyond the small bolt-ons typical of pharma as it battles Eli Lilly in obesity. Traders repeatedly cast VK2735, Viking's GLP-1/GIP dual agonist viewed as a potential tirzepatide rival, as the asset that would make Viking a logical target, and some link the stock's move to Novo's own slide on pipeline concerns; others argue Big Pharma M&A hype around Viking is overblown. No bid or partnership has been confirmed, so the deal talk remains speculation. Underneath is intense anticipation of VK2735's Phase 3 readouts, which many view as the stock's defining upcoming catalyst: bulls say the lack of a pre-data run-up plus heavy short interest sets up a strong reaction, while bears cite GI tolerability risks, slower planned Phase 3 titration, dilution, and criticism of CEO Brian Lian's communication as setup for a sell-the-news disappointment.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO's conversation is dominated by frustration over its collapsed monthly distribution, which has shrunk to less than a penny per share, sparking a wave of questions about why payouts 'fell off a cliff,' when the ex-dividend date is, and whether the fund is still worth holding for income. The explanation circulating among holders is that, as a futures-based Bitcoin ETF, BITO pays distributions out of realized gains when its futures contracts roll, so Bitcoin's weak, rangebound price action has left little realized profit to distribute. The community is split: some long-term holders remain focused on future payouts and argue distributions still exceed their unrealized losses, while others say there is 'no reason to hold' without meaningful dividends and are openly abandoning or questioning the position.

Underlying the dividend debate is a broader argument over Bitcoin itself and the fund's direction. Bears point to a still-unfolding downtrend, futures decay risk, and BITO tracking a broader market selloff, while some chartists see a potential bottom forming in the low-to-mid $60Ks on Bitcoin and expect a distribution-driven payout recovery only if Bitcoin trends higher again. Bulls continue to frame BITO as a leveraged-income way to play a Bitcoin rebound, but the immediate draw is the dividend collapse and what it signals about the fund's mechanics in a flat or falling Bitcoin market.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending on regulatory-clarity speculation, with the Clarity Act  the crypto market-structure bill that would split SEC and CFTC oversight of digital assets  dominating the conversation. Traders are debating the bill's fate after a procedural vote to begin debate: some blame senators who voted against it and accuse Democrats of blocking it for political reasons ahead of the midterms, while others insist the vote was merely procedural. Several community members link the token's brief pump and subsequent fade to Clarity Act headlines, though skeptics counter that HBAR is unlikely to sustain a move until the bill actually passes. A secondary thread covers Grayscale's withdrawal of its HBAR ETF filing, which some traders speculate contributed to the pullback and others dismiss as irrelevant to the long-term thesis. Sentiment is otherwise split, with long-term holders citing network growth, enterprise adoption, and infrastructure build-out, while frustrated traders point to rejected resistance near $0.08, bearish technicals, and suspected market-maker manipulation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A steep, tech-led melt-up toward record territory is dominating the conversation, with much of the community characterizing it as an unexplained, low-volume pump fueled by short squeezes and heavy 0DTE call buying. Bulls point to AI/tech strength and optimism over a potential Trump-Xi trade deal and Iran peace progress, while bears argue the rally conflicts with the Fed's hawkish rate-hike stance, elevated yields and high oil prices, and expect a pullback.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin's breakout to its highest level since January is lifting crypto-linked stocks and has pushed Coinbase to multi-month highs, though many traders complain the stock is lagging the moves in Bitcoin and MSTR. The community is split between bulls calling for a short squeeze and citing the SEC's tokenized-stock exemption and Coinbase's new retail IPO-allocation access as catalysts, and bears arguing the weak relative price action leaves the stock vulnerable to filling gaps lower.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD's rally to a $1 trillion market cap is dominating the conversation, with the chipmaker joining Nvidia, Broadcom, and Micron among U.S. chip companies to reach the milestone after a run of more than 175% year-to-date. Retail sentiment has turned extremely bullish, and traders frame AMD as the "indispensable" No. 2 AI-chip supplier to Nvidia, with the milestone fueling FOMO-style buying chatter and repeated questions like "why is this up so much?" and "how does this not sell off?"The community is split on sustainability. Squeeze believers say short sellers are "getting wrecked," warn against shorting the move, and note the stock has climbed roughly $170 during the rally, while one trader cites a personal rule that companies reaching $1 trillion fall 15% within four weeks afterward. Valuation skeptics counter that the stock trades near $623 against roughly $2.65 in EPS, argue it can't keep climbing "with no major news other than a 10% price increase," and question buying at all-time highs, with several debating whether to lock in profits or wait for a pullback. Others tie the strength to AI chip-demand optimism around Meta's Muse-driven demand bets and AMD's OpenAI partnership. Speculation about pending company news, unverified insider-selling claims, and complaints about algo-driven market manipulation also circulate.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending on bullish discussion centered on its clinical catalyst calendar. Traders are most focused on an anticipated IDE clearance for the company's Keytruda (pembrolizumab) combination trial  framed by the community as the near-term trigger  along with the expanded IMPACT pancreatic cancer study, which grew from 12 to roughly 4850 patients after physician demand, and upcoming GBM scan readouts. Posts repeatedly cite strong interim results, including a 100% response rate in the Keytruda combination and 100% local disease control in pancreatic patients, as the core bull case alongside a signed Tolmar commercial partnership. Contributing factors traders mention behind the stock's recent strength include a roughly 24% gain over a recent ten-session stretch, the TASE dual-listing announcement, MSCI index inclusion, and an analyst price-target increase from Barclays. The main debate is valuation and participation: bulls argue the market hasn't priced in the multi-trial pipeline and that institutions and momentum traders have yet to arrive, while others point to months of short pressure and note that, as a pre-revenue company, the stock's trajectory hinges on catalysts that remain unconfirmed.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma ($HELP) is drawing heavy attention amid volatile trading following a steep run-up and pullback. Traders largely attribute the rally to the appointment of a new CEO  industry veteran Eric Halstead, formerly of Intra-Cellular Therapies  with some speculating he was brought in to position the company for a sale, rather than to any new clinical results, and many characterize the pullback as profit-taking. The community is split ahead of an anticipated Phase 3 topline readout for the company's deuterated psilocybin candidate in depression: bulls point to completed Phase 3 enrollment, founder insider purchases, a TD Cowen price-target hike, and momentum across the psychedelic sector (Compass Pathways' regulatory progress, DFTX's Phase 3 GAD success, and atai-related deal activity), while bears warn of dilution risk  citing a prior $50M convertible and expectations of an offering to fund the roughly $100M+ needed to reach commercialization  and note approval remains years away. A recurring side debate pits $HELP against $CMPS over which psilocybin program is more practical, particularly around washout requirements for patients already on SSRIs.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

Maase Inc. (MAAS), the China-based AI company formerly known as Highest Performances Holdings, is drawing attention for a steady stream of contract announcements around its token-based AI services business. Traders repeatedly cite a RMB1.65M contract with completed client acceptance and full payment, a RMB10M-plus Zhongchuang Liankong enterprise AI deal targeted for Q3 delivery, an RMB7.68M signing, and company claims that its Lingyan Miaoyu LLM is generating B2B revenue  which bulls read as evidence the AI pivot is producing real revenue and clean execution rather than just headlines. The conversation splits between bulls highlighting the repeatable news flow alongside a chart they describe as consolidating above key moving averages with expanding volume, and cautious traders asking why the stock still sold off after positive news and waiting for price-and-volume confirmation and short-interest data before chasing. Smaller threads cover the AI security white paper, its energy-delivery and mobile-robot initiatives, and a national entrepreneurship competition award.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Not your daddy

$PATH someone called me out on my &#39;some mudhaphukkas buy the dip while other mudhaphukkas suck...posts   I am basically saying the following  
  
high conviction is adding when the price action stays broken for months.   
   
When the broader market keeps making fresh highs and your top position just grinds lower week after week, that extended price action causes serious self doubt. It makes you question your judgment, your thesis, and your patience. It is easy to feel confident when the chart validates you. It is a completely different discipline to stay grounded when a stock acts like it is heading for liquidation while the fundamental story remains intact.   
   
Over time, you learn that the market isn&#39;t here to give you daily validation. The best asymmetric setups usually feel terrible right up until they don&#39;t.   
   
True conviction means looking past extended noise, and letting the process play out without needing the chart to tell you you&#39;re right every morning, especially in small caps